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Abstract 
Alterations in cellular levels of the second messenger 3'-5'-cyclic adenosine monophosphate [cAMP]i 
regulate a wide range of physiologically important cellular signalling processes in numerous cell types. 
Osteoclasts are terminally differentiated, multinucleated cells specialised for bone resorption. Their systemic 
regulator, calcitonin, triggers morphometrically and pharmacologically distinct, retraction (‘R’) and 
quiescence (‘Q’), effects respectively on cell-spread area and protrusion-retraction motility paralleling its 
inhibition of bone resorption. Q effects were reproduced by cholera toxin-mediated Gs-protein activation 
known to increase [cAMP]i, unaccompanied by the [Ca
2+
]i changes contrastingly associated with R effects. 
We explore a hypothesis implicating cAMP-signalling involving guanine nucleotide-exchange activation of 
the small GTPase Ras-proximate-1 (Rap1) by exchange proteins directly activated by cAMP (Epac). Rap1 
activates integrin clustering, cell adhesion to bone matrix, associated cytoskeletal modifications and 
signalling processes, and transmembrane transduction functions. Epac activation enhanced, whereas Epac 
inhibition or shRNA-mediated knockdown compromised the appearance of markers for osteoclast 
differentiation and motility following receptor activator of nuclear factor kappa-Β ligand (RANKL) 
stimulation. Deficiencies in talin and Rap1 compromised in vivo bone resorption producing osteopetrotic 
phenotypes in genetically modified murine models. Translational implications for an Epac-Rap1 signalling 
hypothesis in relationship to N-bisphosphonate actions on prenylation and membrane localisation of small 
GTPases are discussed. 
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3'-5'-cyclic adenosine monophosphate in the regulation of specialised cell types 
Alterations in cellular levels of the key second messenger 3'-5'-cyclic adenosine monophosphate [cAMP]i 
take place with alterations in the balance between its generation and hydrolysis. The messenger is generated 
by the activity of a range of adenylyl cyclase isoforms following hormone or neurotransmitter-mediated 
activation of their coupled heterotrimeric G-protein, Gsα. Its subsequent hydrolysis to 5’AMP is brought 
about by one or more of a range of cAMP phosphodiesterases (PDEs)
1
. The resulting intracellular cAMP 
concentration, [cAMP]i, influences a wide range of physiologically important cellular signalling processes. 
The exact processes affected and the nature of their regulation varies with the particular specialisation of the 
cells concerned. Osteoclasts exemplify a terminally differentiated, highly specialised cell type which 
degrade mineralized matrix during normal and pathological bone turnover. Following the proliferation and 
migration of hemopoietic osteoclast progenitors to bone and their differentiation and fusion to form these 
multinucleated cells, osteoclast function involves their migration to and between resorption sites, prior to 
highly specialised and closely regulated resorption episodes terminated by cell retraction and  regulated both 
by local extracellular Ca
2+
 and systemic calcitonin action
2
. 
 
Components of osteoclast motility and retraction properties following calcitonin action: 
the ‘Q’ and ‘R’ effects 
Long-range regulation of osteoclast activity involves calcitonin action, for which  [cAMP]i complements 
intracellular Ca
2+ 
concentration, [Ca
2+
]i as a cellular second messenger
3,4
. These two messenger systems 
exert distinct physiological effects consistent with their representing distinct activation pathways. 
Nevertheless both culminate in inhibition of bone resorptive activity. Calcitonin increased cAMP levels in 
both bone
5
 and isolated osteoclasts
6
. In isolated rat osteoclasts, the lowest effective calcitonin concentrations 
replicated the effects of agents known directly to elevate [Ca
2+
]i including elevated extracellular [Ca
2+
], and 
perchlorate and ionomycin challenge
7
. They induce retraction (‘R’ effect) of cell spread area and inhibit 
bone resorptive activity over 2-3 h following stimulus application whilst sparing cellular motility in the form 
of cell retraction and protrusion activity. These effects accompanied transient elevations in [Ca
2+
]i
8
. These 
effects were not replicated by calcitonin analogues such as amylin or calcitonin gene-related peptide 
(CGRP), yet the latter are similarly known to reduce bone resorption
9
.  
 
However, higher calcitonin concentrations additionally induced a quiescence (‘Q’ effect) in osteoclast 
motility, reflected in a cessation of cell retraction and protrusion activity that was distinct from the R 
effect
10
. It also reduced the margin ruffling implicated in resorptive hemivacuole formation and bone 
resorptive activity and increased secretion of the osteoclast-specific enzyme tartrate-resistant acid 
phosphatase (TRAP). The Q effect could be selectively replicated in an absence of the R effect by the 
calcitonin analogues amylin, β-CGRP
9
, or the peptide CGRP fragment CGRP-(Val
8
Phe
37
), findings also 
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accompanied by reduced bone resorption
9,11
. However, in contrast to agents associated with the R effect, 
none of these latter manoeuvres elevated osteoclast [Ca
2+
]i
9
. The Q effect was associated with reductions in 
supernatant TRAP and reduced osteoclast-mediated bone resorption in vitro.  
 
These Q and R effects could be separated firstly by the application of terms quantifying a parameter, ρ, 
describing cell spread area changes resulting from cell retraction (‘R’) and a motility parameter µ summing 
retraction (∆r)-protrusion (∆p) activity during the Q effect in isolated osteoclasts (Fig. 1A)
10
. These 
demonstrated that calcitonin produced time-dependent reductions in both ρ and µ terms (Fig. 1B). In 
contrast, extracellular Ca
2+
 challenge selectively altered the ρ term with relatively little change in µ (Fig. 
1C). Conversely, amylin challenge selectively altered the µ parameter whilst leaving ρ relatively unchanged 
(Fig. 1D). Secondly, use of CGRP-(Val
8
Phe
37
) as a calcitonin antagonist, abolished the calcitonin-induced Q 
but not the R effect of calcitonin. Thus, the Q and R effects of calcitonin action may reflect activation of 
pharmacologically distinct receptor targets and signalling pathways
12
. 
 
G-protein involvement in the Q and R effects: involvement of cAMP signalling 
Different G-protein agonists recapitulated the Q or R effects either in isolation or in combination
4
. The 
universal G-protein agonist tetrafluoro-aluminate (AlF
4-
) produced both Q and R effects together
4
. This was 
accompanied by a concentration-dependent inhibition of bone resorption, yet a paradoxically increased in 
TRAP enzyme secretion
13
. Pertussis toxin has been previously implicated in Gi/o protein inhibition. In 
osteoclasts, it selectively induced an R effect, in the absence of an Q effect, suggestive of a novel Ca
2+
 
dependent G-protein mediated mechanism. Thus, as also reported in connection with platelet aggregation 
and activation
14
, as well as a number of other cell types
15
, pertussis toxin may exert effects that increase 
osteoclastic [Ca
2+
]i independent of its previously established ADP-ribosylation action on Gi/o. These findings 
were accompanied by reduced bone resorption though a relatively limited reduction in enzyme release. In 
contrast, the Q effect was replicated selectively, in the absence of an R effect, with  challenge by the Gs 
protein stimulator cholera toxin
13,16
. This was similarly accompanied by a reduction in bone resorption but 
an enhanced TRAP secretion. The latter effects likely were mediated by an increase of [cAMP]i  previously 
attributed to cholera toxin induced Gs protein activation. Thus, they were mimicked by the adenylate cyclase 
activator forskolin
16
 and dibutyryl cyclic AMP
17,18
, and potentiated by the phosphodiesterase inhibitor 
theophylline
17
.  
 
Protein kinase A vs. Epac mediated pathways involving cAMP 
The [cAMP]i-mediated actions inhibiting cellular function in the bone-resorbing osteoclast following 
calcitonin action complement their classically described activating effects in cardiomyocytes. The latter 
follow β1 adrenergic stimulation which results in a cAMP-induced activation of protein kinase A (PKA) 
mediated phosphorylation activity of a wide range of regulatory molecules involved in cellular Ca
2+
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signalling. Thus, PKA-mediated L-type Ca
2+
 channel phosphorylation enhances inward voltage-dependent 
L-type Ca
2+
 current and extracellular Ca
2+
 entry resulting from such channel opening during action potential 
excitation. The consequent sarcoplasmic reticular (SR) ryanodine receptor (RyR2)-Ca
2+
 channel mediated 
Ca
2+
-induced Ca
2+
 release is further increased with RyR2 phosphorylation. These phosphorylation events 
thus markedly accentuate the elevations in systolic cytosolic [Ca
2+
] resulting from excitation-contraction 
coupling. Conversely, PKA-mediated phosphorylation of the inhibitory peptide phospholamban increases 
the SR Ca
2+
-ATPase mediated uptake of Ca
2+
 from cytoplasm to SR that reduces cytosolic [Ca
2+
] to its 
background level during cardiomyocyte relaxation
19
.  
 
However, cAMP also exerts PKA-independent effects. In sino-atrial node cells, cAMP binding to 
hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels mediating pacemaker (If) ionic currents 
increases heart rate
20
. Furthermore, there has been much recent interest about the role of exchange proteins 
directly activated by cAMP (Epac)
21–24
. In cardiomyocytes, Epac signaling offers an alternative or co-
existent cAMP-dependent regulatory mechanism that operates downstream of β adrenergic receptor 
activation but upstream of the RyR2-mediated Ca
2+
-induced SR Ca
2+
 release underlying excitation-
contraction coupling
25,26
. Thus, the cAMP analog 8-(4-chlorophenylthio)-2’-O-methyladenosine 3’, 5’-
cyclic monophosphate (8-CPT) when applied at concentrations preferentially activating Epac rather than 
PKA
27
 elicited spontaneous, or increased amplitudes of electrically evoked, cytosolic Ca
2+
 transients, as well 
as spontaneous propagated cytosolic Ca
2+
 waves, in rat or mouse cardiac myocytes
23
. Such phenomena 
potentially increase electrogenic Na
+
/Ca
2+
 exchange current activity accounting for the pro-arrhythmic 
triggering electrophysiological activity that was observed accompanying such alterations in Ca
2+
 
homeostasis
23,28–32
. These effects also followed isoproterenol-mediated adrenergic agonist activation in the 
presence of the PKA inhibitor H-89
33
. They thus appear to reflect a cAMP-mediated, PKA-independent 
regulatory mechanism, specifically acting on excitation-contraction coupling through modulation of RyR2 
activation
23
. Thus they were abolished with genetic ablation of Epac2, β1 adrenoreceptor, Ca
2+
/calmodulin-
dependent protein kinase II-δ (CaMKIIδ) and RyR2-S2814 phosphorylation
34
. Furthermore, murine Epac1
-/-
, 
Epac2
-/-
 and CaMKIIδ
-/-
 hearts showed normal indices for other cardiac functions. These included in vivo 
cardiac structure, ratios of heart to body weight, cardiac contractility or pressure overload–induced 
hypertrophy, and their responses to adrenergic dobutamine challenge, and cellular SR Ca
2+
-ATPase and 
Na
+
/Ca
2+
 exchanger protein expression levels, and Ca
2+
 content
34
. 
 
Since their discovery, Epac proteins have been implicated in a wide range of critical physiological actions of 
cAMP
35
. The present article speculates on a possible role for this system in osteoclast function in the context 
of available evidence. Epac exists in three isoforms. Of these, Epac1, Epac2 and Repac all include a Ras-
association domain (RA)
36
 (Fig. 2). Epac1 and Epac2 are membrane bound proteins reflecting their 
possession of a dishevelled-Egl-10-pleckstrin (DEP) domain. Epac1 contains a regulatory, cyclic 
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mononucleotide-binding (CNB) domain with a natively disordered, N-terminal extension
37
 permitting 
activation by direct cAMP binding
38,39
. Epac2 contains an additional lower affinity amino-terminal cAMP-
binding (CNB) site
37,40
. This is N-terminal to the DEP domain and has a 20-fold lower cAMP affinity than 
the conserved CNB. These regulatory domains are joined via a Ras exchange motif (REM) and an 
intervening RA domain to the cell division cycle phosphatase-25 (CdC25) homology domain (CDC25HD) 
responsible for guanine nucleotide-exchange activity. The isoform related to Epac, Repac, only includes a 
catalytic region, consistent with it being constitutively active or having a separate regulatory site
37,41
.  Of the 
isoforms directly regulated by cAMP, cellular expression of Epac1 appears ubiquitous, whereas Epac2 
occurs preferentially in brain, pituitary, and adrenal gland. In contrast to Epac1 and to the apparent [Ca
2+
]i-
independence of the osteoclastic Q effect, Epac2 has been associated with regulation of processes dependent 
upon Ca
2+
 signaling
25,42
. Thus, besides producing growth arrest in neuroendocrine cells, Epac2 located at 
cardiomyocyte transverse tubules may regulate potentially arrhythmogenic SR Ca
2+
 leak and/or Ca
2+
 
induced Ca
2+
 release through SR RyR2-Ca
2+
 release channels
23,43
. Epac2 has also been implicated in 
endoplasmic reticular Ca
2+
 dependent secretary events in pancreatic cells
44–48
. It has been suggested that in 
these situations it acts through activation of a novel phosphoinositide (PI) phospholipase C isoform (PLCe), 
protein kinase C (PKC), and CaMKII
35
. Epacs can also function as guanine nucleotide-exchange factors 
(GEFs) facilitating exchange of GDP for GTP binding in small guanine nucleotide-binding (G) proteins. In 
general, GEFs activate signalling by catalyzing the exchange from G-protein-bound GDP to GTP. In 
contrast, GTPase-activating proteins (GAPs) terminate such signalling by inducing GTP hydrolysis. GEFs 
promote the GTP-bound, active, form. GAPs promote the GDP-bound, inactive, form (Fig. 3). Both GEFs 
and GAPs contain multiple domains mediating regulation by both extracellular signals and localized 
events
49
. 
 
Rap1 as a target for Epac-mediated regulation 
Amongst the small guanine nucleotide-binding (G) proteins that cycle between GDP- and GTP-bound 
forms, Ras proteins, resident at the cytoplasmic surface of cell membranes, are of particular importance. 
They act as cellular switches in signal transduction
50
. The Ras-proximate or Ras-related proteins (Rap) 
constitute one group within the Ras protein superfamily
39
.  These contain a C-terminal tetrapeptide sequence 
motif Cys-Ali-Ali-X, where Ali is an aliphatic amino acid and X is any amino acid. This constitutes the site 
of membrane attachment via isoprenylation for ras, nuclear lamins and γ-subunits of the heterotrimeric G-
proteins. Rap1 is thus localized to the cytosolic side of internal membranes such as endosomes and secretory 
granules compatible with roles in recruiting components for vesicle formation and/or transport.  
 
In contrast to Ras, in which mutations are associated with cell proliferation and human neoplasms, genetic 
studies suggest that of Rap proteins, Rap1 is primarily involved in cell adhesion and cell junction 
formation
51
. Rapl proteins, exist as two similar isoforms in many animal tissues,  Rap1a and Rap1b, 
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differing by only a few amino acids
42,51
. Rap2a (previously Rap2) proteins are found mostly in platelets and 
brain tissue. They have been less extensively studied than Rap1, but have been implicated in Epac2-
dependent growth arrest in neuroendocrine cells, and Ca
2+
-dependent secretary events in pancreatic cells
44,45
. 
Rap2b has been reported in Escherichia coli systems.  
 
Ras and Rap are regulated by different GEFs and GAPs
52
. Epac is likely one of a range of these GEFs 
regulating the Rap1 member of this family (Fig. 3). Thus, in addition to transmembrane receptors such as 
receptor tyrosine kinases, heterotrimeric G-protein-coupled receptors, cytokine receptors and cell-adhesion 
molecules
53
, common second messengers such as cAMP, Ca
2+
 and diacylglycerol appear involved in 
transducing extracellular signals to Rap1
54
. Rap1 can also be activated by PKA-mediated phosphorylation 
but the functional significance of this is unclear but may even concern Rap1 inactivation
55
, activation of 
other messengers such as B-raf 
56
, and involve an indirect, Ca
2+
-dependent pathway
57
.  
 
Rap1 has been implicated in a range of processes dependent on integrin-dependent activation, exemplified in 
its requirement for phagocytosis by mouse macrophages and by Dictyostelium discoideum. It is also 
implicated in other processes that might involve integrin-mediated cell adhesion, morphogenesis, 
haematopoiesis, leukocyte migration and tumour invasion. It has been suggested that Rap1 activates 
integrins by stimulating cell surface receptors through currently uncertain mechanisms
58–61
. Rap1 has also 
been implicated in the recruitment to and activation of Phg2 at the leading edge of chemotaxin D. 
discoideum cells required for myosin II phosphorylation and disassembly in pseudopodial formation 
62
.  
 
Epac modification alters osteoclast development and function 
The selective Epac activator, 8-CPT, enhanced, whilst the Epac inhibitor brefeldin A reduced the osteoclast 
differentiation that followed stimulation by receptor activator of nuclear factor κ-Β ligand (RANKL)
63
 in 
primary murine and human bone marrow culture studies. Such differentiation accompanied cellular 
morphological alterations from centrally-sited nuclei surrounded by a ring of F-actin and absence of 
podosomes to large multinucleate osteoclasts with a peripheral podosome belt, showing TRAP production.  
 
Similar findings were made in RAW264.7 cells in which these findings were further confirmed by the 
additional, recently available, Epac activation inhibitors 4-methylphenyl-2,4,6-trimethylphenylsulfone (ESI-
05) and 3-[5-(tert-butyl)isoxazol-3-yl]-2-[2-(3-chlorophenyl)hydrazono]-3-oxopropanenitrile (ESI-09). 
Silencing either Epac1 or Epac2 by shRNA prevented this differentiation in the RAW264.7 cells. These 
findings were reflected in mRNA levels of the differentiation markers cathepsin K, nuclear factor of 
activated T cells c1 (NFATc1) and osteopontin, and reduced numbers of formed resorption pits in dentine 
slides. The findings paralleled reductions in RANKL-induced Rap1 activation, and in reduced activation of 
proteins that were involved in actin cytoskeletal changes. The latter included reductions in the Ras homolog 
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RhoA, involved in stress fibre formation, cell cycle regulation and cell development, and Ras-related C3 
botulinum toxin substrate 1 (Rac1), involved in lamellipod formation and cell-cell adhesion, with Epac1 or 
Epac2 suppression. They included reductions in cdc42, involved in filopodial assembly, with Epac1, but not 
Epac2, suppression and reductions in focal adhesion kinase (FAK), involved in cellular adhesion, with 
Epac2, but not Epac1, suppression
64,65
. Direct activation of Rac1 and FAK is necessary for actin 
cytoskeleton rearrangements during osteoclast differentiation. Finally, Epac1 or Epac2 silencing reduced the 
RANKL-induced cytoplasm to nuclear translocation of p50/p105 nuclear factor κ-light-chain-enhancer of 
activated B cells (NFκB) associated with normal osteoclast differentiation
66
.  
 
Integrins are potential effectors for Rap1 in regulating osteoclast motility and bone 
resorption 
Integrins form a family of heterodimeric adhesion receptors involved in cell–matrix and cell–cell 
interactions central to a wide variety of cell functions, including leukocyte homing and activation, cell 
responses to mechanical stress, apoptosis, and tumour growth and metastases
67
. Osteclast motile and 
secretory activity similarly involve integrin-dependent, cell–matrix and cell–cell interactions
68
. Osteoclast 
activity involves cell migration, adhesion to bone surfaces, and formation of a tight clear sealing zone that 
encloses a resorption lacuna. After insertion of secretory vesicles, a ruffled border comprising a highly 
convoluted membrane facing the bone surface is formed.  
 
Mammalian osteoclasts express the αvβ3 integrin/vitronectin receptor, at high levels, as well as the 
collagen/laminin receptor α2β1 and the vitronectin/fibronectin receptor αvβ1
69
. The α and β integrin 
cytoplasmic domains do not themselves have enzymatic activities. However, integrins interact with a range 
of matrix, and cytoskeletal and signaling molecules (Fig. 4). First, integrins mediate osteoclast adhesion to 
the bone surface by interacting with extracellular matrix proteins within the bone matrix. Rat osteoclasts 
adhere in an αvβ3-dependent manner to matrix proteins containing RGD (Arg-Gly-Asp) sequences, including 
vitronectin, osteopontin, bone sialoprotein and a cryptic RGD-site in denatured collagen type I, and in a 
α2β1- and RGD-dependent manner to collagen type I
70,71
. Correspondingly, antibodies raised to α2, β1 and 
αvβ3 inhibit bone resorption
72,73
. Second, integrin-ligand binding induces receptor clustering causing 
formation of focal adhesion contacts, recruitment of and linkage to cytoskeletal molecules including 
paxillin, vinculin, gelsolin and F-actin with an organisation of intracellular cytoskeletal complexes, 
additionally leading to changes in cell shape, spreading and motility
74,75
. Thirdly, integrins mediate 
transmembrane transduction of signals in both inside-out and outside-in directions relating organization of 
the actin network and the composition of the focal adhesions, through the cytoskeletal protein talin which 
links integrins to the actin cytoskeleton, and is an essential mediator of integrin activation
76
. Fourthly, a 
wide range of signaling pathways including those involving phosphatidylinositol 3-kinase, c-Src, protein 
tyrosine kinase 2 β (PYK2) and p130
cas 
are
 
 αvβ3 integrin-dependent
77,78
.  
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Rap1 and its interaction with integrins are essential to osteoclast bone resorptive activity 
Studies in genetically modified murine models suggest that both Talin and Rap1 are critical for osteoclastic 
bone resorptive activity in vivo
79
. Talin1-deficient osteoclast precursors showed normal osteoclast 
differentiation markers following exposure to macrophage colony-stimulating factor (M-CSF) and RANKL. 
However, they showed compromised attachment to and migration over bone substrate. The talin-deficient 
mice correspondingly showed osteopetrotic phenotypes. Mice with a talin deletion made late in the course of 
osteoclastogenesis showed a reduction in both ovariectomy-induced osteoporosis and periarticular osteolysis 
associated with inflammatory arthritis. Osteoclast-specific deletion of Rap1 (CtsK-Rap1), which promotes 
talin/β-integrin recognition, also yielded mice with an osteopetrotic phenotype. In both these examples, this 
was more severe, with up to fivefold increases in bone mass, than the phenotype associated with αvβ3-
deficiency, likely due to the additional added failed activation of β1 integrins.  
 
Translational implications of Epac and Rap1 signalling: relationships to bisphosphonate 
action 
A possible translational outcome of testing a hypothesis implicating involvements of Epac regulation of 
Rap1 activity in osteoclast function may include targeted therapeutic intervention with reduced side effects, 
directed at bone diseases. Of these, osteoporosis is a widespread, often initially asymptomatic, insidious, 
disease of progressive bone loss and skeletal deterioration increasing fragility and liability to bone fracture. 
Its manifestations become commoner with age, particularly in postmenopausal women, affecting <1 in 2 
women and <1 in 5 men over age 50 y. Bisphosphonates provide effective therapy: postmenopausal 
women receiving alendronate for 10 years showed fewer clinical vertebral fractures than those altered to 
placebo at 5 years in the Fracture Intervention Trial Long-term Extension (FLEX)
80
. Similarly, women 
who received 6 annual infusions of zoledronic acid showed fewer vertebral fractures than those altered to 
placebo after 3 years in the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly–
Pivotal Fracture Trial (HORIZON) extension
81
. Experimental studies report that relatively high (~10 µM) 
concentrations of nitrogen-containing bisphosphonates prevent post-translational prenylation of small 
GTPases not only in Rac, Rho, Cdc42, and Rab but also in Rap1 proteins, not only in J774 macrophages but 
also osteoclasts in vitro and in vivo
82,83
. This effect was attributed to inhibition of cholesterol biosynthetic 
pathways generating farnesyl pyrophosphate and geranyl diphosphate
84
 substrates for post-translational 
protein prenylation. Prenylation of small GTPases enables their localization to the correct subcellular 
membranes and interaction with regulatory proteins
85
. Conversely, inhibition of such protein geranyl-
geranylation by nitrogen containing bisphosphonates resulted in cytoskeletal disruption, reduced resorptive 
activity and osteoclast apoptosis
86,87
. Although the concentrations at which these effects occurred are 
unlikely to be reached in clinical practice, these findings broadly draw attention to Rap1 prenylation as a 
potential therapeutic target amenable to upstream approaches to therapy through the Epac-Rap signalling 
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system. This could lead to alternative treatment strategies potentially avoiding some side effects of 
conventional bisphosphonate therapy
88,89
.  
 
Summary of abbreviations. 
∆p, cell protrusion increment; ∆r, cell retraction increment; 5’AMP, 5’ adenosine monophosphate; 8-CPT, 8-(4-
chlorophenylthio)-2’-O-methyladenosine 3’, 5’-cyclic monophosphate;  A, cell spread area; CaMKII, 
Ca2+/calmodulin-dependent protein kinase II; cAMP, 3'-5'-cyclic adenosine monophosphate;  CdC25, cell division 
cycle phosphatase-25; CDC25HD, CdC25 homology domain; CGRP, calcitonin gene-related peptide; CNB, cyclic 
mononucleotide-binding domain; DEP, dishevelled-Egl-10-pleckstrin domain; Epac, exchange protein directly 
activated by cAMP; ESI-05, 4-methylphenyl-2,4,6-trimethylphenylsulfone; ESI-09, 3-[5-(tert-butyl)isoxazol-3-yl]-2-
[2-(3-chlorophenyl)hydrazono]-3-oxopropanenitrile; FAK, focal adhesion kinase; FLEX, Fracture Intervention Trial 
Long-term Extension; GAP, GTPase-activating protein; GDP, guanine diphosphate; GEF, guanine nucleotide-
exchange factor; GTP, guanine triphosphate;  Gx, guanine nucleotide-binding protein [x = s, stimulatory, i, inhibitory, 
o, other); HCN, hyperpolarisation-activated cyclic nucleotide-gated; HORIZON, Health Outcomes and Reduced 
Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial; If, sino-atrial node pacemaker current; M-CSF, 
macrophage colony-stimulating factor;  µ, cell motility parameter; NFATc1, nuclear factor of activated T-cells, 
cytoplasmic 1;  NFκB, nuclear factor κ-light-chain-enhancer of activated B cells; PDE, phosphodiesterase; PI, 
phosphoinositide; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; PYK2, Protein 
tyrosine kinase 2β; Q, cell quiescence; R, cell retraction; Rac1, Ras-related C3 botulinum toxin substrate 1; 
RANK, nuclear factor κ-Β; RANKL, nuclear factor κ-Β ligand; Rap, Ras-proximate or Ras-related protein; Ras, rat 
sarcoma; RA, Ras association domain; REM, Ras exchange motif; Repac, related to Epac; ρ, cell retraction parameter; 
RGD, Arg-Gly-Asp; RhoA, Ras homolog A;  RyR2, ryanodine receptor type 2; SR, sarcoplasmic reticulum; t, time; 
TRAP, tartrate-resistant acid phosphatase. 
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Figure legends 
 
Figure 1. Osteoclast motility properties.  
(A) Measurement by overlaying cell margin outlines obtained at successive 2 min intervals (numbered 1-4) 
in time, t, in order to measure changes in normalised cell spread area ρ=A(t)/A(t0) and protrusion ∆p and 
retraction ∆r activity at the cell margin, used to derive an index for cell motility µ = (∆p  + ∆r)/A(t). The 
effect of (B) 300 pM human calcitonin (hCT) (C) 20 mM extracellular [Ca
2+
] and (D) 250 nM amylin 
applied at t = 0, on motility and cell spread area. Note that calcitonin affects both but extracellular [Ca
2+
] 
and amylin selectively influence the time course of one of the two parameters µ or ρ (reproduced by 
permission from 
10
).      
 
Figure 2. Basic organization of Epac isoforms.  
In Epac1 the regulatory region contains membrane localizing dishevelled-Egl-10-Pleckstrin (DEP) and 
regulatory, cyclic mononucleotide-binding (CNB) domains. Epac2 further includes an additional CNB 
domain N-terminal to the DEP domain. The regulatory domains are joined via a Ras exchange motif (REM) 
and a ras association (RA) domain to the CdC25 homology domain (CDC25HD) responsible for GEF 
activity. The isoform related to Epac, Repac, only includes the catalytic region. 
 
Figure 3. Rap1 activation by the Epac signalling system 
Activation of Epac by the direct action of cAMP (A) enhancing the guanine nucleotide-exchange factor 
(GEF) function of Epac. (B) The increased exchange of GDP for GTP binding results in activation of the 
Ras-proximate-1 (Rap1).  
 
Figure 4. Consequences of osteoclast integrin activation  
Following (A) activation by Rap1, αvβ3 integrins (B) mediate osteoclast adhesion to the bone surface by 
interacting with extracellular bone matrix proteins containing RGD (Arg-Gly-Asp) sequences, including 
vitronectin, osteopontin and bone sialoprotein. Integrin-ligand binding induces receptor clustering causing 
formation of focal adhesion contacts, recruitment of cytoskeletal molecules with organisation of intracellular 
cytoskeletal complexes leading to changes in cell shape, spreading and motility. Integrins also mediate 
transmembrane transduction of signals in both inside-out and outside-in directions relating organization of 
the actin network and the composition of the focal adhesions, through the cytoskeletal protein talin which 
links integrins to the actin cytoskeleton. Finally, a wide range of phosphatidylinositol 3-kinase, c-Src, PYK2 
and p130
cas 
signaling pathways are
 
αvβ3 integrin-dependent.  
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